Recent protocols have identified the NLRP3 inflammasome as a crucial factor in the development of cardiomyopathies and atrial fibrillation (AF), suggesting a potential pathway for novel therapeutic agents [99]. Here, NLRP3 is linked to atrial fibrillation.